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OBJECTIVE — Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascu-
larOutcomesinPatientsWithType2DiabetesMellitus(HEART2D)isamultinational,randomized,
controlledtrialdesignedtocomparetheeffectsofprandialversusfastingglycemiccontrolonriskfor
cardiovascular outcomes in patients with type 2 diabetes after acute myocardial infarction (AMI).
RESEARCH DESIGN AND METHODS — Patients (type 2 diabetes, aged 30–75 years)
wererandomlyassignedwithin21daysafterAMItothe1)prandialstrategy(PRANDIAL)(three
premeal doses of insulin lispro targeting 2-h postprandial blood glucose 7.5 mmol/l) or the 2)
basal strategy (BASAL) (NPH twice daily or insulin glargine once daily targeting fasting/premeal
blood glucose 6.7 mmol/l).
RESULTS — Atotalof1,115patientswererandomlyassigned(PRANDIALn557;BASALn
558),andthemeanpatientparticipationafterrandomizationwas963days(range1–1,687days).The
trial was stopped for lack of efﬁcacy. Risks of ﬁrst combined adjudicated primary cardiovascular
eventsinthePRANDIAL(n174,31.2%)andBASAL(n181,32.4%)groupsweresimilar(hazard
ratio0.98[95%CI0.8–1.21]).MeanA1CdidnotdifferbetweenthePRANDIALandBASALgroups
(7.7  0.1 vs. 7.8  0.1%; P  0.4) during the study. The PRANDIAL group showed a lower daily
meanpostprandialbloodglucose(7.8vs.8.6mmol/l;P0.01)and2-hpostprandialbloodglucose
excursion(0.1vs.1.3mmol/l;P0.001)versustheBASALgroup.TheBASALgroupshowedlower
mean fasting blood glucose (7.0 vs. 8.1 mmol/l; P  0.001) and similar daily fasting/premeal blood
glucose (7.7 vs. 7.3 mmol/l; P  0.233) versus the PRANDIAL group.
CONCLUSIONS — Treating diabetic survivors of AMI with prandial versus basal strategies
achieved differences in fasting blood glucose, less-than-expected differences in postprandial
blood glucose, similar levels of A1C, and no difference in risk for future cardiovascular event
rates.
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C
ardiovascular disease (CVD) is the
leadingcauseofmorbidityandmor-
tality in individuals with diabetes,
for which 65% of deaths are attribut-
able to heart disease or stroke (1,2).
Among individuals with type 2 diabetes,
those with a previous myocardial infarc-
tion have a particularly high risk of addi-
tional cardiovascular events (3).
The higher prevalence of classic car-
diovascular risk factors in type 2 diabetes
only partly explains the increased cardio-
vascular risk associated with diabetes
(2,3). Chronic hyperglycemia increases
this risk (4–7) and postchallenge/
postprandial hyperglycemia has been as-
sociated with CVD independent of A1C
or fasting blood glucose (FBG) (8,9). In-
creased oxidative stress has been sug-
gested as a pathophysiologic mechanism
to explain this relationship (10). Further-
more, acarbose, an -glucosidase inhibi-
tor that speciﬁcally reduces postprandial
hyperglycemia, reduced cardiovascular
mortality in a diabetes prevention trial
(11).
The Diabetes Mellitus, Insulin Glu-
cose Infusion in Acute Myocardial In-
farction (DIGAMI) trial (12)
demonstrated a reduction in mortality
in patients with type 2 diabetes and re-
cent acute myocardial infarction (AMI)
after intensive insulin treatment, and this
study was developed to determine the im-
pact of postprandial hyperglycemia on
CVD in a similar high-risk population.
Thus, the primary objective of the Hyper-
glycemia and Its Effect After Acute Myo-
cardial Infarction on Cardiovascular
OutcomesinPatientsWithType2Diabe-
tes Mellitus (HEART2D) study was to
demonstrate a difference between two in-
sulin strategies, one targeting postpran-
dial hyperglycemia and the other
targeting fasting and interprandial hyper-
glycemia,ontimeuntiltheﬁrstcombined
adjudicated cardiovascular event (pri-
mary outcome deﬁned as cardiovascular
death, nonfatal myocardial infarction,
nonfatal stroke, coronary revasculariza-
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METHODS— HEART2D was a pro-
spective, open-label, randomized, two-
arm parallel, clinical trial conducted at
105 study centers in 17 countries. The
ethicalreviewboardsofparticipatingcen-
ters approved the protocol and informed
consent document. Patients gave written
informed consent to participate in accor-
dance with the Declaration of Helsinki
and Good Clinical Practice guidelines.
The treatment group assignments were
blinded to the sponsor during the trial.
The ﬁrst patient visit occurred on 25 Oc-
tober 2002, and the last patient was en-
rolled on 6 July 2005.
Studydesignandmethodologieshave
been described previously (13). In brief,
patients (aged 30–75 years) with type 2
diabetes (duration of 3 months and not
well controlled with diet therapy alone
nor treated with an intensive insulin reg-
imen) entered the trial within 18 days of
an AMI (without severe myocardial dam-
age). Within 21 days of hospital admis-
sion for the recent AMI, patients were
randomly assigned to one of two treat-
ment groups: 1) the PRANDIAL strategy
that targeted control of postprandial gly-
cemia with administration of mealtime,
thrice-daily insulin lispro (Humalog, Eli
Lilly and Company, Indianapolis, IN) or
2) the BASAL strategy that targeted fast-
ing/interprandial glycemia with adminis-
tration of NPH (Humulin, Eli Lilly and
Company) twice daily or insulin glargine
(Lantus, sanoﬁ-aventis, Paris, France)
oncedaily.Oralantihyperglycemicagents
were discontinued. Both treatments tar-
getedanA1C7.0%,andthePRANDIAL
group had a self-monitored postprandial
blood glucose target of 7.5 mmol/l,
whereas the BASAL group had an FBG/
premeal blood glucose target of 6.7
mmol/l. When the A1C was 8.0% on
two consecutive visits despite meeting
two-thirds of the strategy blood glucose
targets, the PRANDIAL treatment was in-
tensiﬁed by adding NPH at bedtime, and
the BASAL treatment was replaced with
twice-daily biphasic intermediate-acting
insulin (human insulin 30/70). Patients
were to be followed beyond the primary
end point and for up to 7 years.
A 10-member blinded adjudication
board evaluated all reported primary out-
comes, any death, and all cardiovascular
secondary outcomes according to pre-
deﬁned criteria. Outcomes were not con-
sidered serious adverse events (SAEs)
unless they were related to a study drug,
study procedure, or study device. If
the SAE was also a study outcome, then
the SAE was only in the opinion of the
investigator.
Determination of sample size
Thedetailsofthestudysamplesizedeter-
minationwerepublishedpreviously(14).
In summary, to achieve 80% power, 490
patientsmusthaveexperiencedoneofthe
primary combined outcomes to detect a
difference between groups assuming the
following: a difference of 2.5 mmol/l be-
tween groups in postprandial blood glu-
cose (translates into an 18.5% reduction
in the 2-year incidence rate of outcomes),
18 months for patient recruitment, 18
months of patient follow-up after the last
randomly assigned patient, 10% annual
dropout rate, a 2-year outcomes inci-
dence rate of at least 40% for patients in
the least efﬁcacious therapy strategy, and
a nominal two-sided signiﬁcance level of
0.045. Therefore, 1,355 patients were
planned for random assignment with 678
patients in each group. The randomiza-
tion scheme used a minimization tech-
niquetoensurebalanceofdiseaseseverity
across therapy strategies by accounting
for study center, left ventricular ejection
fraction (LVEF) (50%, 50%), paren-
teral administration of insulin within the
ﬁrst 24 h in the coronary care unit, and
planned angiography.
Statistical methods
Unless otherwise noted, statistical analy-
ses were performed for the intent-to-treat
population that included all randomly as-
signedpatientswhotookatleastonedose
of the study drug. All comparisons were
performed using two-tailed tests with a
nominal signiﬁcance level of 0.05. All
conﬁdence intervals were computed as
two-tailed using 95% coverage. Unless
otherwise noted, descriptive statistics are
reportedasmeansSD.Categoricalvari-
ables are reported as frequencies and
proportions.
The time-to-event measures analysis
usedthenumberofdaysfromrandomiza-
tion to the ﬁrst observed cardiovascular
event for each patient. Comparisons were
performed using a two-sided log-rank
test. The hazard ratio (HR) was calculated
as the hazard for the PRANDIAL group
relative to that of the BASAL group.
During the study, measures of A1C,
self-monitored blood glucose, lipids, al-
bumin-to-creatinine ratio, LVEF, and vi-
tal signs were analyzed using a pattern
mixed model for repeated measures. The
model included effects for treatment,
baseline measure, randomization factors,
and an additional factor for pattern (de-
ﬁned as 30, 30 and 42, and 42
months).
Measures of insulin dose and body
weight were analyzed as the end point
value using last observation carried for-
ward for each patient. Comparisons for
continuous variables were performed us-
ing an ANCOVA model incorporating
ﬁxed effects for strategy, baseline, and
randomization factors. Hypoglycemia
rate was analyzed using a nonparametric
test of rank data, and all other continuous
measures were analyzed as parametric





included all new events observed and
those preexisting conditions that in-
creased in severity after randomization.
Four interim analyses were per-
formed when 20, 28, 53, and 67% of the
events were observed. An external group
conducted the analyses that were re-
viewed by an external data monitoring
committee. The ﬁrst three assessed the ef-
fectiveness of glycemic management to
targets,safety,andevaluatedtreatmentef-
fects warranting early study termination.
The last analysis included an additional
guideline for evaluating study futility at a
cutoff of 40% for conditional power as-
suming the trend observed in the interim.
Signiﬁcance levels of 0.001 and 0.0085
wereusedforallinterimanalysestoassess
superiority and inferiority, respectively,
of the PRANDIAL group.
RESULTS
Patient disposition
A total of 1,227 patients were enrolled in
the study (supplemental Fig. 1, available
inanonlineappendixathttp://dx.doi.org/
10.2337/dc08-1671). Of these, 1,115 pa-
tients were randomly assigned and took
at least one dose of the study drug
(PRANDIAL n  557; BASAL n  558).
From this group, 723 (64.8%) were from
Central or Eastern Europe (Croatia, Czech
Republic, Hungary, Poland, Romania, Rus-
sianFederation,Slovakia,andSlovenia),84
(7.5%) were from Western Europe (Ger-
many, Spain, and the U.K.) or Canada, 149
(13.4%) were from Western Asia (Israel,
Lebanon, and Turkey), 70 (6.3%) were
fromIndia,and89(8.0%)werefromSouth
Africa.InthePRANDIALgroup,338com-
pleted the study compared with 346 for
the BASAL group. Fifty-one deaths oc-
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who were discontinued before cessation
of the protocol, 38 in the PRANDIAL
group versus 44 in the BASAL group had
experienced a primary outcome.
Baseline characteristics
The PRANDIAL and BASAL groups were
similar in age, sex, origin, country, BMI,
and duration of diabetes as well as in
other clinically relevant measures (Table
1). In addition, both groups were similar
in prior historical CVD diagnoses (e.g.,
prior myocardial infarction and stroke)
and with regard to interventions received
to open occluded coronary vessels for
their most recent AMI. There were no dif-
ferences in diabetes therapies at baseline
between treatment groups (supplemental
Table 1, available in an online appendix).
Nine percent of patients were managed
withdietandexercise.Themostcommon
oral agents used were sulfonylureas
(26%) and sulfonylureas plus metformin
(15%), and 22% of patients used basal/
premixed insulin once or twice daily.
Other insulin regimens included basal/
premixed insulin plus combination oral
therapy (7%) and combination multiple
daily injection (3 injections/day) (6%).
Primary and secondary
cardiovascular end points
The Data Monitoring Committee recom-
mended stopping the trial because of fu-
tility on 7 June 2007 after the fourth
interim analysis. The sponsor requested
that all active patients be brought in for a
ﬁnal visit and the last patient visit was 26
October 2007.
The mean number of days patients
participated in the trial after randomiza-
tion was 963 (2.7 years) (1–1,687 days).
ThenumberofPRANDIALgrouppatients
experiencing a ﬁrst combined adjudi-
cated cardiovascular event was similar to
that in the BASAL group (n  174
[31.2%] vs. n  181 [32.4%]; HR 0.98
[95% CI 0.8–1.21]) (Fig. 1). Of the 51
deaths in each group, 44 cardiovascular
deaths and 3 fatal strokes occurred in the
PRANDIAL group compared with 42 car-
diovascular deaths and 2 fatal strokes in
the BASAL group. The estimated HR for
individual cardiovascular events (supple-
mental Table 2, available in an online ap-
pendix), combined events (alternatives to
theprimaryendpoint)(supplementalTa-
ble 3, available in an online appendix), or
combined events for those patients
achieving targeted blood glucose goals
(supplementalTable4,availableinanon-
line appendix) did not reach statistical
signiﬁcance. The estimated HR for post
hoc analyses for time to ﬁrst primary out-
come also failed to approach statistical
signiﬁcance for subpopulations (those
achieving A1C 7%, A1C 7%, optimal
blood glucose target values, borderline
blood glucose target values, and nonopti-
Figure1—Fractionofpatientswhodidnotexperienceaﬁrstprimary(combinedcardiovascular)
adjudicated outcome versus days in trial by treatment strategy (PRANDIAL versus BASAL).
Table 1—Baseline characteristics of the intent to treat study population by treatment group
Variable PRANDIAL BASAL P value
n 557 558
Sex 0.680
Female 201 (36.1) 208 (37.3)
Male 356 (63.9) 350 (62.7)
Age (years)
Mean 61.1  9.7 60.9  9.8 0.724
Aged 65 202 (36.3) 220 (39.4) 0.277
Origin 0.302
Caucasian 484 (86.9) 483 (86.6)
Western Asian 61 (11.0) 58 (10.4)
African descent 1 (0.2) 6 (1.1)
Other 11 (2.0) 11 (2.0)
Country 0.999
Duration of diabetes (years) 9.3  7.2 9.0  7.3 0.518
Current tobacco use* 93 (16.7) 81 (14.5) 0.316
Past tobacco use (years)* 13.7  16.5 12.3  15.4 0.143
Weight (kg) 81.12  15.17 81.86  15.86 0.513
BMI (kg/m
2) 29.0  4.6 29.2  5.0 0.380
Overweight (BMI 25 kg/m
2) 449 (80.8) 447 (80.3) 0.832
Systolic blood pressure (mmHg) 126.88  16.63 127.76  17.75 0.346
Diastolic blood pressure (mmHg) 76.60  9.06 76.87  9.56 0.542
Prior myocardial infarction* 99 (17.8) 101 (18.1) 0.858
Thrombolysis (recent AMI)* 97 (17.4) 98 (17.6) 0.970
Intravenous insulin infusion (recent AMI) 160 (28.8) 160 (28.8) 0.807
A1C (%) 8.42  1.40 8.27  1.52 0.089
Triglycerides (mmol/l) 1.89  1.15 1.77  0.95 0.074
Total cholesterol (mmol/l) 4.45  1.25 4.45  1.25 0.871
HDL cholesterol (mmol/l) 0.96  0.25 0.96  0.23 0.607
LDL cholesterol (mmol/l) 2.68  1.02 2.71  1.02 0.556
Urinary albumin-to-creatinine ratio (mg/g) 115  430 163  610 0.171
QTc interval (ms) 435  33 434  34 0.428
LVEF (%) 50.54  10.05 50.97  10.08 0.829
Data are mean  SD or n (%). *Unknown 1.5%.
Raz and Associates
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Cox regression model adjustments for
baseline glycemia and glycemic exposure
(data not shown).
Glycemic measures
A1C did not differ between the
PRANDIAL and BASAL groups (mean 
SEM 7.7  0.1 vs. 7.8  0.1%; P  0.4)
during the study. The A1C values at each
visit throughout the study and at the end
point (last observation carried forward)
were evaluated (Fig. 2A). At the end
point, 28% of PRANDIAL group patients
achieved an A1C 7.0% versus 31% of
BASAL group patients (P  0.236) (A1C
8.0%: PRANDIAL 63% and BASAL
61%; P  0.375).
The self-monitored blood glucose
proﬁles (Fig. 2B) resulted in a daily
mean  SEM over the course of the study
for 2-h postprandial blood glucose of
7.8  0.3 versus 8.6  0.2 mmol/l (P 
0.01) and postprandial blood glucose ex-
cursion of 0.1  0.2 versus 1.3  0.1
mmol/l (P  0.001) for the PRANDIAL
and BASAL groups, respectively. Simi-
larly,FBGwas8.10.2versus7.00.2
mmol/l (P  0.001) and daily mean FBG/
premealbloodglucosewas7.70.2ver-
sus 7.3  0.2 mmol/l (P  0.233) for the
PRANDIAL and BASAL groups, respec-
tively. Approximately 47% of patients in
the PRANDIAL group achieved the blood
glucose target of 7.5 mmol/l for daily
mean postprandial blood glucose, and
46% in the BASAL group achieved daily
mean FBG/premeal blood glucose 6.7
mmol/l.
Cardiovascular risk factors and
medications
Lipids were similar between groups
(PRANDIAL versus BASAL) throughout
the course of the study: triglycerides
2.21  0.16 vs. 2.18  0.16 mmol/l (P 
0.894); total cholesterol 4.65  0.11 vs.
4.65  0.11 mmol/l (P  0.997); HDL
cholesterol 1.14  0.02 vs. 1.11  0.02
mmol/l (P  0.523); and LDL cholesterol
2.65  0.09 vs. 2.70  0.09 mmol/l (P 
0.719).
Blood pressure was similar between
groups (PRANDIAL versus BASAL) for
both systolic (131.8  1.7 vs. 132.4 
1.6mmHg;P0.782)anddiastolicpres-
sures (77.4  0.9 vs. 77.5  0.9 mmHg;
P  0.978). In addition, heart rate
(71.41.0vs.71.11.0beats/min;P
0.817), LVEF (54.3  1.30 vs. 52.39 
1.22%; P  0.257), and corrected QT in-
terval(423.83.43vs.424.12.91ms;
P  0.952) were also similar.
Thefrequencyofconcomitantcardio-
vascular drug use was high and similar
between groups (PRANDIAL versus
BASAL:95.0vs.95.9%;P0.478).With
the exception of -blockers (PRANDIAL
versus BASAL: 83.7 vs. 78.9%; P 
0.046), the other most frequent cardio-
vascular medications were used similarly
betweengroups:ACEinhibitorsorangio-
tensin receptor blockers (86.3%), statins
(76.4%), and aspirin (88.1%).
Body weight and insulin doses
At the end point, the PRANDIAL com-
pared with the BASAL group gained
slightly more weight (4.8  8.0 vs. 3.1 
7.1 kg; P  0.001) and received a greater
insulindose(0.600.39vs.0.520.35
units/kg; P  0.001). Regimen intensiﬁ-
cation occurred more frequently in the
PRANDIAL group (28%) versus the
BASAL group (21%) (P  0.005).
Safety: hypoglycemia and adverse
events
The incidence of hypoglycemia (all) was
similar between groups through visit 8
(when this information was collected)
(PRANDIAL versus BASAL: 55.3 vs.
55.2%; P  0.367), and the incidence of
severe hypoglycemia was also similar
throughout the trial (PRANDIAL versus
BASAL: 12.9 vs. 9.5%; P  0.071). The
incidence of nocturnal hypoglycemia
(through visit 8), however, was greater in
the BASAL group than in the PRANDIAL
group (10.6 vs. 6.1%; P  0.007).
Irrespective of treatment, adverse
eventswerereportedby63.6%ofpatients
overall:366patients(65.7%)and343pa-
tients (61.5%) in the PRANDIAL and
BASAL groups, respectively. The three
most common adverse events overall
(Medical Dictionary for Regulatory Activ-
ities preferred terms) were nasopharyngi-
tis (6.5%), hypertension (4.9%), and
peripheral edema (4.6%). A signiﬁcant
treatmentdifferencewasnotedforcardiac
failure, with patients in the PRANDIAL
Figure 2—Glycemic measures. A: Mean  SD A1C at each visit by treatment strategy
(PRANDIAL versus BASAL). B: Seven-point mean self-monitored blood glucose proﬁles at
baseline (dotted line) and throughout the study (postrandomization, solid line) by treatment
strategy (PRANDIAL versus BASAL).
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than those in the BASAL group (2.3 vs.
0.7%, respectively; P  0.030); however,
congestive cardiac failure occurred simi-
larly(2.2vs.2.3%;P0.999),and,thus,
therewasnodifferencebetweenstrategies
when the categories were combined.
SAEs were reported in 289 patients
(25.9%) overall: 144 (25.9%) and 145
(26.0%) in the PRANDIAL and BASAL
groups, respectively. The four most com-
mon SAEs, irrespective of treatment
group, were congestive cardiac failure
(1.5%), hypoglycemia (1.3%), pneumo-
nia (1.1%), and chest pain (1.1%). A
signiﬁcant treatment difference was
noted in the incidence of sepsis (P 
0.038), with more events in the PRAN-
DIALgrouprelativetotheBASALgroup
(5 vs. 0, respectively).
CONCLUSIONS — HEART2D is the
ﬁrst study to examine the effect of a re-
duction in postprandial glucose on car-
diovascular mortality and morbidity.
Interim analysis demonstrated no differ-
ence between PRANDIAL and BASAL
treatmentswithrespecttoriskfortheﬁrst
combined adjudicated cardiovascular
event in type 2 diabetic patients with a
recent AMI, and the trial was halted for
statistical futility under advice of the Data
Monitoring Committee. Essentially simi-
lar overall glycemic control, measured by
A1C, was achieved in both treatment
arms of the trial, but the PRANDIAL
group had consistently lower postpran-
dial glycemia compared with the BASAL
group, and the latter had consistently
lower fasting glycemia.
There is strong epidemiological evi-
dence that postchallenge/postprandial
plasma glucose levels independently pre-
dictCVDevents,andevidencethatfasting
plasma glucose levels are predictive is
muchweaker(8,9).Thesefactsimplythat
targets for A1C and postprandial glucose
levels are important to achieve, not only
to reduce the risk of microvascular com-
plications, but also to reduce the risk of
CVD morbidity and mortality in individ-
uals with diabetes.
Postprandial hyperglycemia has been
associatedwithincreasedoxidativestress,
inﬂammation, endothelial dysfunction,
decreased ﬁbrinolysis, plaque instability,
and cardiac events (10). A direct and pro-
portionalassociationexistsbetweenpost-
prandial hyperglycemia and both
coronary artery disease and cardiac
events. The postprandial hyperglycemia
hypothesis has been supported by inter-
ventional studies demonstrating that re-
duced postprandial glycemia and lipids
decrease inﬂammation and improve en-
dothelial function (15) and are associated
withalesserdegreeofatheroscleroticpro-
gression (14,16,17). The HEART2D
study succeeded in creating two groups
with comparable A1C levels and similar
proportions of patients achieving blood
glucose targets, despite clear differences
between postprandial glucose and fasting
glucose. More importantly, however, the
A1C values did not reach the goal of
7.0%. Perhaps there may have been re-
luctance to intensively optimize glycemia
in a population with a high risk for a car-
diovascular event. In addition, neither a
2.5mmol/ldifferenceinpostprandialgly-
cemia between groups nor the 40% event
rate was achieved as assumed for the
power calculations.
The DIGAMI trial (12), which in-
cluded both type 1 and type 2 diabetic
patients with recent AMI, demonstrated
at 1 year of follow-up a signiﬁcant reduc-
tion in mortality between groups and an
0.5% separation in A1C. A similar sep-
aration in glycemic control was noted in
the PROspective pioglitAzone Clinical
Trial In macroVascular Events (PROactive)
study(18),inwhichtheprimarycompos-
ite cardiovascular end point failed to
reach signiﬁcance between therapies, but
the secondary composite end point did
reach signiﬁcance.
On the other hand, the subsequent
DIGAMI-2 study (19) failed to establish
any glycemic separation between treat-
mentgroups,andnodifferencewasnoted
in cardiovascular outcomes. It has been
speculated that the results of the two
DIGAMI trials may have been explained
by glycemic exposure during chronic di-
abetes care as opposed to the acute glyce-
micintervention(20).Itissigniﬁcantthat
the recent results of three large, well-
designed clinical trials of glycemic inter-
ventions to improve cardiovascular
outcomes in type 2 diabetes failed to pro-
vide conclusive results. The Action to
Control Cardiovascular Risk in Diabetes
Study Group (ACCORD) trial (21) dem-
onstrated increased mortality with inten-
sive glycemic goals (A1C of 6.4%), the
Action in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled
Evaluation(ADVANCE)trial(22)showed
similar cardiovascular outcomes with
similarly achieved intensive glycemic
goals, and the VA Diabetes Trial (VADT)
(23) results demonstrated that patients
with a shorter duration of type 2 diabetes
may obtain cardiovascular beneﬁt with
intensive control, but diabetic patients
with a longer duration of type 2 diabetes
may experience greater risk for adverse
outcomes with intensive glycemic goals.
Although the mean glycemic exposure as
measuredbyA1CinHEART2Dmayhave
been similar to that with the standard
therapies in these trials, post hoc analysis
based on overall glycemic exposure
(A1C) produced the same results as the
primary analysis.
The null results of HEART2D may be
explainedbytheadvancedstateofCVDin
the patients studied. Retarding the pro-
gression of advanced atherosclerosis may
be very difﬁcult, similar to observations
with advanced microvascular complica-
tions. Many cardiovascular events oc-
curred early in the course of HEART2D,
indicating extension or progression of
preexisting disease. Recent studies differ
from DIGAMI and suggest that lower lev-
els of glycemia and postprandial hyper-
glycemia with or without a previous
cardiovascular event may require many
years to produce favorable effects on car-
diovascular events (5,21–24). Further-
more, the effects of other risk factor
reduction (hypertension and lipids, espe-
cially LDL), which were similar between
the groups, may be greater than glycemia
on cardiovascular outcomes. Of note, the
use of concomitant cardiovascular medi-
cal therapy was more prevalent (e.g., as-
pirin, statins, and ACE inhibitors) in
HEART2D than in DIGAMI. Therefore,
correctingriskfactorswithcardiovascular
medications and improved technical in-
terventions (compared with DIGAMI)
during the course of this trial may have
obscured the effect of glycemic interven-
tiononcardiovascularoutcomes.Someof
these therapies may also counterbalance
theadverseeffectsofpostprandialglucose
on oxidative stress (25). In addition, the
difference in glycemic control achieved
between the groups was more modest
than had been predicted at the start of the
clinical trial. Greater separation in post-
prandial blood glucose (the goal was 2.5
mmol/lpostprandialbloodglucosediffer-
ence between strategies) than that ob-
served in HEART2D may be needed to
adequatelytestthehypothesis.Moreover,
overall glycemic goals were not fully real-
ized, and a lower A1C level or a much
larger sample size may be needed to dis-
tinguish between components of the di-
urnal glucose proﬁle.
The HEART2D study implemented
strategies to target either fasting/premeal
Raz and Associates
DIABETES CARE, VOLUME 32, NUMBER 3, MARCH 2009 385or postprandial blood glucose control in
patients with type 2 diabetes who had
survived a myocardial infarction. Modest
differences in postprandial and fasting
blood glucose were achieved during the
study, but relatively similar A1C levels
were obtained with both treatment strat-
egies. The magnitude of the differences in
postprandial glycemia was less than ex-
pected,andtheriskofCVDoutcomeswas
similar between the treatment groups.
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